Document ID: chunk:federal_register_of_legislation:F2024L01542:reg:52:p1
Version: federal_register_of_legislation:F2024L01542
Segment Type: reg
Provision Reference: reg 52 (pt 1/6)
Character Range: 4514–7669

52  Prescriptions directing special arrangement supply
  Despite the amendment of this instrument by the amending instrument:
 (a) a prescription written before 1 December 2024 for the special arrangement supply of an HSD pharmaceutical benefit that has an EFC transition drug continues, on and after that date, to be a prescription for a special arrangement supply of an HSD pharmaceutical benefit; and
 (b) for the purposes of supply of the pharmaceutical benefit, on or after 1 December 2024, on the basis of the prescription:
 (i) the pharmaceutical benefit is taken to be an HSD pharmaceutical benefit; and
 (ii) daunorubicin with cytarabine is taken to be a CAR drug.
 1.                    Schedule 1, omit entry for Daunorubicin with cytarabine
 2.                    Schedule 1, entry for Epoprostenol
     (a) omit:
   Powder for I.V. infusion 500 micrograms (as sodium) with 2 vials diluent 50 mL  Injection  Flolan  C13491 C13505 C13506 C13510 C13512 C13577 C13634     See Schedule 2  See Schedule 2

     (b) omit:
   Powder for I.V. infusion 1.5 mg (as sodium) with 2 vials diluent 50 mL  Injection  Flolan  C13491 C13505 C13506 C13510 C13512 C13577 C13634     See Schedule 2  See Schedule 2

 1.                    Schedule 1, entry for Lenalidomide in each of the forms: Capsule 5 mg; and Capsule 10 mg
     omit:
         Cipla Lenalidomide  C13782 C13785 C13786 C13787 C13791 C13801 C13803 C13804 C13805 C13810 C13811 C13812 C13813 C14362     See Schedule 2  See Schedule 2

 1.                    Schedule 1, entry for Lenalidomide in the form Capsule 15 mg
     omit:
         Cipla Lenalidomide  C13782 C13785 C13786 C13787 C13791 C13803 C13804 C13805 C13811 C13812 C13813 C14362     See Schedule 2  See Schedule 2

 1.                    Schedule 1, entry for Lenalidomide in the form Capsule 25 mg
     omit:
         Cipla Lenalidomide  C13782 C13785 C13786 C13787 C13803 C13805 C13811 C13812 C13813 C14362     See Schedule 2  See Schedule 2

 1.                    Schedule 1, entry for Nevirapine in the form Tablet 200 mg
     omit:
         Nevirapine Alphapharm  C4454 C4512     120  5

 1.                    Schedule 1, omit entry for Nivolumab with relatlimab
 2.                Schedule 1, entry for Vedolizumab
     insert in numerical order in the column headed "Circumstances": C16169 C16170 C16181 C16216 C16217
 1.                Schedule 1, after entry for Zoledronic acid in the form Injection concentrate for I.V. infusion 4 mg (as monohydrate) in 5 mL [Brand: DEZTRON; Maximum quantity: 1; Maximum repeats: 0]
     insert:
         Zoledronate-DRLA 4  C5605 C5703 C5704 C5735 C9268 C9304 C9317 C9328 C14729 C14735  P14729 P14735  1  0

 1.                Schedule 1, entry for Zoledronic acid in the form Injection concentrate for I.V. infusion 4 mg (as monohydrate) in 5 mL [Brand: Zoledronate-DRLA 4; Maximum quantity: 1; Maximum repeats: 11]
          1.            insert in numerical order in the column headed "Circumstances": C14729 C14735
          2.            insert in numerical order in the column headed "Purposes": P5605 P5703 P5704 P5735 P9268 P9304 P9317 P9328
 1.                Schedule 2, omit